The vaccine industry is alert and ready to respond to the Omicron variant of COVID-19 should it enter the country. Along with the Philippine medical community, it reiterates that the public can still receive ample protection from it through current and future anti-variant countermeasures like rapid changes in the COVID-19 vaccines, a faster vaccination campaign, and the strict observance of health protocols like social distancing.
Enrique Gonzalez, Founder, and Chairman of IP-Biotech (IPB), says that the vaccine providers will be exercising agility to continually respond to the Omicron variant as it evolves. He assures the public that “the world’s vaccine industry is ready to respond with specific Omicron booster shots by making changes to the existing vaccines if the need arises. The production infrastructure is in place, and ramping up for next generations can be a rapid process.”
IPB is the leading vaccine service provider and the local Emergency Use Authorization (EUA) holder of Coronavac’s SINOVAC COVID-19 vaccine which has provided 50 percent of all COVID-19 vaccines in the Philippines in 2021.
